Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Feature|Videos|July 18, 2024

Overcoming Delivery Challenges of mRNA Therapeutics

The key to advancing mRNA therapeutics lies in developing more efficient and versatile delivery systems that can overcome challenges around stability, targeting, and safety.

This discussion segment centered around the need for improved mRNA delivery systems to advance therapeutics. Experts spoke about the importance of developing efficient and versatile delivery systems, such as LNPs, to target mRNA molecules to specific cell types or tissues. They also highlighted the need for delivery systems that can overcome shelf life or storage conditions, minimize adverse immune responses, and utilize self-amplifying mRNA delivery systems. The consensus was that delivery is the key to unlocking the full potential of mRNA therapeutics.

Discussion Topics

  • 00:07 - Identifying key advances needed to move the mRNA therapeutics field forward
  • 01:18 - Importance of developing efficient and versatile mRNA delivery systems
  • 01:49 - Overcoming mRNA product storage and shelf life limitations
  • 04:35 - Challenges and opportunities with LNP-based mRNA delivery, especially for solid organs

Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.
The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.